Jefferies Financial Group Inc. Acquires 542,162 Shares of Embecta Corp. $EMBC

Jefferies Financial Group Inc. lifted its stake in Embecta Corp. (NASDAQ:EMBC) by 40.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,884,875 shares of the company’s stock after acquiring an additional 542,162 shares during the period. Jefferies Financial Group Inc.’s holdings in Embecta were worth $26,596,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in EMBC. Tower Research Capital LLC TRC grew its position in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares in the last quarter. Humankind Investments LLC purchased a new stake in Embecta during the 2nd quarter worth about $111,000. Neuberger Berman Group LLC bought a new position in Embecta in the 3rd quarter worth about $143,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Embecta by 7.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock valued at $145,000 after buying an additional 1,093 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Embecta during the 2nd quarter valued at about $147,000. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EMBC. BTIG Research reissued a “buy” rating and issued a $25.00 price target on shares of Embecta in a report on Friday, February 6th. Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $18.50.

Embecta Stock Performance

NASDAQ:EMBC opened at $9.07 on Monday. Embecta Corp. has a 52-week low of $9.06 and a 52-week high of $15.55. The stock has a fifty day moving average of $11.08 and a 200 day moving average of $12.74. The firm has a market capitalization of $537.13 million, a price-to-earnings ratio of 3.83 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last announced its earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The business had revenue of $261.20 million for the quarter, compared to analyst estimates of $258.07 million. During the same period in the prior year, the company earned $0.65 EPS. The company’s quarterly revenue was down .3% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Equities analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 6.6%. The ex-dividend date is Friday, February 27th. Embecta’s dividend payout ratio is 25.32%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.